After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Gilead Sciences is voluntarily withdrawing cancer drug Trodelvy from the U.S. market as a treatment for advanced cases of urothelial carcinoma, a move that comes nearly five months after the ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. Before filing for global regulatory approvals, the ...

US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries. The announcement ...

Gilead Sciences plans to voluntarily withdraw U.S. accelerated approval for Trodelvy in metastatic urothelial cancer. The decision followed results from the TROPiCS-04 study, which failed to meet ...

Gilead Sciences (GILD) closed the latest trading day at $83.79, indicating a -0.24% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.25%.

Many middle-income countries are left out of the deal, widening a gulf in access to critical medicines. By Stephanie Nolen Stephanie Nolen has covered the global H.I.V. pandemic for more than 25 ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it has signed royalty-free licensing agreements with six pharmaceutical manufacturers to manufacture and supply generic versions of the ...

(RTTNews) - Foster City, California-based Gilead Sciences, Inc. is recalling one lot of Veklury (remdesivir) for Injection 100 mg/vial for treating COVID-19, to the consumer level, due to the ...

Oct 2 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its ...

Gilead Sciences GILD underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...